International COVID-19 trial to restart with focus on immune responses https://www.nature.com/articles/d41586-021-01090-z
Excited to announce that the clinical trial of Impentri in patients with #COVID19 associated ARDS has been approved. Hope to recruit the first patient soon.
Two highly relevant, recent @Nature papers have been published to deepen our understanding of the potential benefit of imatinib for the treatment of #Covid_19:
Results published on Friday 18 June in The Lancet Respiratory Medicine show that oral imatinib, currently used to treat cancers, reduces mortality by 49% in hospitalized COVID-19 [...]
IMPENTRI will look for clinical proof of the benefit of imatinib in Covid-19 acute respiratory distress syndrome The build-up of fluid in the lungs is common among [...]
CAMBRIDGE, UK AND DUBLIN, IRELAND, May 13 2020 / / — Exvastat (Ireland) Ltd, a privately held biopharmaceutical company backed by Cambridge Innovation Capital, today announced the [...]